Henry Broeska, PhD

Henry Broeska, Ph.D. Henry Broeska is an American-Canadian Ph.D. researcher from Irvine, California. Henry began writing software for healthcare systems in the mid-1990s, which led him to international locations, especially India, where he became involved in various medical projects for the next five years. In 2009, Henry collaborated with neurologists at a research hospital in Pune, MH, India, to co-develop a novel method to treat the injured blood-brain barrier (BBB) of MS patients with their stem cells. He is the co-author of the study entitled The Effectiveness of Selective Stem Cell Placement on Gait Performance in Patients with Multiple Sclerosis: A Phase I Clinical Trial  published in 2019 in the International Journal of Pharmaceutical Sciences and Drug Research. He has also recently achieved a patent entitled “Methods and Compositions for Treating Vascular-related Degenerative Neurological Disorders.” In 2015 Henry permanently relocated from Canada to the United States, where he continues to pursue his medical research at the University of California Irvine (UCI). Besides his neuro-research pursuits, Henry is currently the lead investigator for the NIH-registered Provider Insurance Revenue Study (‘PIRStudy’). This investigation is designed to provide evidence of change and reasons for the differences in the revenues of American physicians before and after the advent of the COVID-19 pandemic. In addition, Henry remains active in the advocacy movement for health care reform in the United States.